EQRx Reveals Two New Assets For Low-Cost Drug Pipeline

The start-up launched in January with $200m to develop lower-priced drugs against known targets. Now it has licensed a CDK4/6 inhibitor from G1 Therapeutics and an EGFR inhibitor from Hansoh.

Dollar_Sign_Pills — EQRx aims to develop effective drugs at lower prices • Source: Shutterstock

EQRx Inc. made a big splash at the start of 2020 when it launched with $200m in series A venture capital, not to chase novel drug targets or modalities, but to develop small molecules and antibodies against well-known targets. The goal wasn’t to be first to market, but to have the cheapest drug. Now the company has disclosed license agreements for two cancer drugs in blockbuster categories – still without revealing its strategy for bringing less expensive medicines to market.

Cambridge, MA-based EQRx and G1 Therapeutics Inc. announced on 23 July that EQRx will pay G1, headquartered in Research...